In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.
January 27, 2022: Lonza Group to collaborate with HaemaLogiX Ltd., to manufacture next clinical batch of multiple myeloma drug candidate, KappaMab.
December 08, 2021: ThermoGenesis Holdings, Inc. to join hands with Contract Development Manufacturing Organization (CDMO) to make Cell and Gene therapies available to the maximum patients.
Ans: Increasing prevalence of blood cancer, and other hematopoietic disorders is estimated to boost the market growth.
Ans: The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2022 – 2031.
Ans: The major players in the market are Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., CSG-BIO Company, Inc. (CellSave), CBR Systems, Inc., Pluristem Inc., ViaCord, LLC, and Cynata Therapeutics Limited.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by transplant type, disease type, application, and by region.
Ans: The bone marrow transplant (BMT) segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Ans: Very high cost of stem cell transplant is estimated to hamper the market growth.
Ans: The North America region is anticipated to provide more business opportunities over the forecast period on the back of growing incidences of blood cancer in the region.
Submit Your Request For Proposal (RFP)
Submit RFP Buy Now Download Research Report Sample